In Q1 2026, Perceptive Advisors held 84 positions worth $5.0B. They initiated 13 new positions and exited 131. Their largest holding was PRAX ($656.0M). Portfolio value shrank -3.5% versus the prior quarter.
Frequently asked questions
What stocks did Perceptive Advisors own in Q1 2026?
Perceptive Advisors held 84 biotech stocks in their 13F portfolio in Q1 2026. Their top positions include PRAX, CELC, ASND, ROIV, CNTA. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Perceptive Advisors's portfolio worth in Q1 2026?
Perceptive Advisors's tracked biotech portfolio was worth $5.0B across 84 positions, with total assets under management of approximately $8B. Portfolio values are based on 13F filings with the SEC.
What did Perceptive Advisors buy in Q1 2026?
Perceptive Advisors initiated 13 new positions in Q1 2026, including IONS, DAWN, DMRA, DBVTF, STRO and 8 more. They also increased 27 existing positions.
What did Perceptive Advisors sell in Q1 2026?
Perceptive Advisors fully exited 131 positions in Q1 2026, including JANX, PYXS, TEM, TRIB, QURE and 126 more. They also trimmed 31 existing positions.
Is Perceptive Advisors a biotech fund?
Clinical-stage biotech specialist known for deep scientific due diligence and concentrated bets on binary catalysts like FDA approvals and pivotal trial readouts. Edelman and team leverage decades of pattern recognition in drug development to identify asymmetric risk/reward setups.
Want AI analysis, insider signals, and catalyst overlays for Perceptive Advisors?
View latest Perceptive Advisorsportfolio →